Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Cardiovascular primary prevention: how high should we set the bar?

Prasad V, Vandross A.

Arch Intern Med. 2012 Apr 23;172(8):656-9; discussion 659. doi: 10.1001/archinternmed.2012.812.

PMID:
22529231
[PubMed - indexed for MEDLINE]
2.

Drug Class Review on Fixed Dose Combination Drug Products for the Treatment of Type 2 Diabetes and Hyperlipidemia: Final Report [Internet].

McDonagh M, Peterson K, Thakurta SG, Dana T.

Portland (OR): Oregon Health & Science University; 2007 Oct.

PMID:
20496342
[PubMed]
Books & Documents
3.

Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.

Charland SL, Malone DC.

Curr Med Res Opin. 2010 Feb;26(2):365-75. doi: 10.1185/03007990903484802.

PMID:
19995326
[PubMed - indexed for MEDLINE]
4.

Rosuvastatin-induced arrest in progression of renal disease.

Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG.

Cardiology. 2004;102(1):52-60. Epub 2004 Apr 2.

PMID:
15073451
[PubMed - indexed for MEDLINE]
5.

Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.

Yim BT, Chong PH.

Ann Pharmacother. 2003 Jan;37(1):106-15. Review.

PMID:
12503944
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk